Under the terms of the agreement, Crucell will receive an upfront payment, milestone payments, annual maintenance fees, and royalties on net product sales. Other financial details were not disclosed.
Crucell’s AdVac technology is a recombinant vector technology used to develop novel adenoviral-based products.The company’s PER.C6 technology is based on a human cell line developed for the large-scale manufacture of biological products including vaccines.